Elicio Therapeutics, Inc. - Common Stock — Liquidità Trimestrale (NASDAQ:ELTX) | MetaTrader

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 28.18 M28.14 M29.53 M28.28 M25.86 M22.69 M Totale passività 39.49 M19.24 M27.69 M24.47 M24.23 M24.13 M Patrimonio netto totale -11.31 M8.9 M1.83 M3.82 M1.64 M-1.44 M Totale passività e patrimonio netto 28.18 M28.14 M29.53 M28.28 M25.86 M22.69 M Debito totale 20.03 M09.34 M9.72 M9.41 M9.47 M Indebitamento netto 2.42 M-18.35 M-12.75 M-10.89 M-9.16 M-5.47 M

Notizie

Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out

Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?

Elicio Therapeutics lancia una nuova offerta azionaria at-the-market da 100 milioni di dollari

H.C. Wainwright alza il target su Elicio Therapeutics a 17$

H.C. Wainwright raises Elicio Therapeutics price target to $17

Rodman & Renshaw avvia la copertura su Elicio Therapeutics con rating buy

Rodman & Renshaw initiates Elicio Therapeutics stock with buy rating

Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?

Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why

Elicio riporta diffusione antigenica nell’87% dei pazienti oncologici valutati

Elicio reports antigen spreading in 87% of evaluated cancer patients

Elicio Therapeutics nomina Marc Wolfgang come Chief Technology Officer